thalidomide has been researched along with Diffuse Mixed Small and Large Cell Lymphoma in 45 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (31.11) | 29.6817 |
| 2010's | 30 (66.67) | 24.3611 |
| 2020's | 1 (2.22) | 2.80 |
| Authors | Studies |
|---|---|
| Ambinder, R; Cheever, M; Ekwede, I; George, J; Goncalves, PH; Gulley, JL; Lurain, K; Mangusan, R; Ramaswami, R; Uldrick, TS; Wang, HW; Widell, A; Yarchoan, R | 1 |
| Bartlett, NL; Blum, KA; Cheson, BD; Hsi, ED; Jung, SH; Leonard, JP; Martin, P; Pitcher, B; Ruan, J; Shea, T; Smith, SE | 1 |
| Bai, H; Fan, WJ; Fan, ZQ; Wu, T | 1 |
| He, W; Min, X; Yang, X | 1 |
| Abramson, JS; Advani, RH; Andreadis, CB; Bartlett, N; Bellam, N; Byrd, JC; Czuczman, MS; Dwyer, MA; Fayad, LE; Glenn, MJ; Gockerman, JP; Gordon, LI; Harris, NL; Hoppe, RT; Horwitz, SM; Kelsey, CR; Kim, YH; Krivacic, S; LaCasce, AS; Nademanee, A; Naganuma, M; Porcu, P; Press, O; Pro, B; Reddy, N; Sokol, L; Swinnen, L; Tsien, C; Vose, JM; Wierda, WG; Yahalom, J; Zafar, N; Zelenetz, AD | 1 |
| Berardi Vilei, S; Berthod, G; Caspar, C; Eckhardt, K; Fischer, N; Hitz, F; Mey, U; Pabst, T; Zucca, E | 1 |
| Chang, MN; Hou, W; Jung, SH; Li, Y | 1 |
| Czuczman, MS; Habermann, TM; Li, J; Lossos, IS; Pietronigro, D; Reeder, CB; Tuscano, JM; Vose, JM; Witzig, TE; Zinzani, PL | 1 |
| Abedi, M; Brunson, A; Chee, K; Dutia, M; O'Donnell, RT; Reed-Pease, C; Tuscano, JM; Welborn, J | 1 |
| Argnani, L; Cox, MC; Devizzi, L; Di Rocco, A; Fabbri, A; Fattori, PP; Rigacci, L; Rossi, G; Storti, S; Tura, S; Vitolo, U; Zaccaria, A; Zaja, F; Zinzani, PL | 1 |
| Buske, C | 1 |
| Baladandayuthapani, V; Claret, LC; Davis, RE; Fanale, MA; Fayad, LE; Feng, L; Fowler, NH; Hagemeister, FB; Kwak, LW; McLaughlin, P; Muzzafar, T; Nastoupil, L; Neelapu, SS; Oki, Y; Orlowski, RZ; Rawal, S; Romaguera, JE; Samaniego, F; Shah, J; Tsai, KY; Turturro, F; Wang, M; Westin, JR | 1 |
| Costa, LJ; Dermer, SJ; Kumar, S; Stowell, SA | 1 |
| Choquet, S; Hoang-Xuan, K; Houillier, C; Martin-Duverneuil, N; Mokhtari, K; Navarro, S; Soussain, C; Touitou, V | 1 |
| Chiappella, A; Czuczman, MS; Fowler, N; Goy, A; Habermann, TM; Hernandez-Ilizaliturri, FJ; Nowakowski, GS; Vitolo, U; Witzig, TE | 1 |
| Coyle, M; Evens, AM; Kritharis, A; Sharma, J | 1 |
| Cheson, BD; Crawford, J | 1 |
| Rosen, ST; Siddiqi, T | 1 |
| Cheah, CY; Fayad, LE; Fowler, NH; Hagemeister, FB; LeBlanc, D; Nastoupil, LJ; Neelapu, SS; Samaniego, F | 1 |
| Ar, MC; Salihoglu, A; Soysal, T | 1 |
| Baldini, L; Bari, A; Buda, G; Carella, AM; Cesaretti, M; Chiapella, A; Di Raimondo, F; Ferrari, A; Guardigni, L; Marcheselli, L; Marcheselli, R; Molinari, AL; Musto, P; Pozzi, S; Ronconi, S; Sacchi, S; Santoro, A; Silvestris, F; Specchia, G; Vallisa, D | 1 |
| Galanina, N; Nabhan, C; Petrich, A | 1 |
| Argnani, L; Cox, MC; Devizzi, L; Di Rocco, A; Fabbri, A; Fattori, PP; Rigacci, L; Rossi, G; Storti, S; Vitolo, U; Zaja, F; Zinzani, PL | 1 |
| Cole, CE; Ervin-Haynes, A; Habermann, TM; Justice, G; Lam, W; Lossos, IS; McBride, K; Pietronigro, D; Takeshita, K; Tuscano, JM; Vose, JM; Wiernik, PH; Wride, K; Zeldis, JB | 1 |
| Czuczman, MS; O'Connor, OA | 1 |
| Wiernik, PH | 1 |
| Cole, C; Ervin-Haynes, A; Justice, G; Kaplan, H; Moore, T; Pietronigro, D; Reeder, C; Takeshita, K; Voralia, M; Vose, JM; Wiernik, PH; Witzig, TE; Zeldis, JB | 1 |
| Cheson, BD; Friedberg, JW; Kahl, BS | 1 |
| Hagemeister, FB | 1 |
| Rummel, M | 1 |
| Ahmadi, T; Carver, JR; Chong, EA; Nasta, S; Schuster, SJ; Stonecypher, M; Wheeler, JE | 1 |
| Basak, GW; Jaksic, O; Koristek, Z; Labar, B; Masszi, T; Mayer, J; Mikala, G; Wiktor-Jedrzejczak, W | 1 |
| Buckstein, R; Czuczman, MS; Ervin-Haynes, A; Li, J; Pietronigro, D; Polikoff, J; Reeder, CB; Vose, JM; Witzig, TE; Zinzani, PL | 1 |
| Gauthier, J; Leleu, X; Wémeau, M; Yakoub-Agha, I | 1 |
| Apperley, JF; Basak, GW; Douglas, KW; Duarte, RF; Gabriel, IH; Geraldes, C; Hübel, K; Jaksic, O; Koristek, Z; Kröger, N; Lanza, F; Lemoli, R; Malard, F; Mikala, G; Mohty, M; Selleslag, D; Worel, N | 1 |
| Jäger, U | 1 |
| Gibson, AD; Klem, J; Price, N; Reddy, GK | 1 |
| Björkholm, M | 1 |
| Lindley, KJ; Milla, PJ; Ramsay, AD; Shah, N; Thapar, N | 1 |
| Czuczman, MS; Hernandez-Ilizaliturri, FJ; Holkova, B; Ottman, E; Reddy, N | 1 |
| Bellizzi, AM; Cathro, HP; Lommatzsch, SE; Rosner, MH | 1 |
| Bartlett, NL; Cheson, BD; Grinblatt, D; Johnson, JL; Niedzwiecki, D; Rizzieri, D; Smith, SM | 1 |
| Chanan-Khan, AA; Cheson, BD | 1 |
| Corral, LG; Fleming, YW; Stein, B; Zhu, D | 1 |
| D'Orazio, AI | 1 |
12 review(s) available for thalidomide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
[Research and Applications Progress of Lenalidomide in Relapsed / Refractory Blood System Diseases -Review].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Thalidomide | 2018 |
A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Cyclophosphamide; Doxorubicin; Humans; Immunologic Factors; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Prednisone; Rituximab; Thalidomide; Treatment Outcome; Vincristine | 2015 |
Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 2: adoptive cellular immunotherapy, small-molecule inhibitors, and immunomodulation.
Topics: Aniline Compounds; Antineoplastic Agents; Clinical Trials as Topic; Humans; Immunomodulation; Immunotherapy, Adoptive; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Prognosis; Protein-Tyrosine Kinases; Purines; Quinazolinones; Randomized Controlled Trials as Topic; Recurrence; Sulfonamides; Thalidomide; Treatment Outcome | 2015 |
Novelties in the management of B-cell malignancies: B-cell receptor signaling inhibitors and lenalidomide.
Topics: Angiogenesis Inhibitors; B-Lymphocytes; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Signal Transduction; Thalidomide | 2015 |
The evolving role of lenalidomide in non-Hodgkin lymphoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; Immunologic Factors; Immunomodulation; Lenalidomide; Lymphoma, Non-Hodgkin; Signal Transduction; Thalidomide; Treatment Outcome | 2016 |
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Non-Hodgkin; Protease Inhibitors; Pyrazines; Thalidomide | 2008 |
Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Salvage Therapy; Thalidomide; Venous Thromboembolism; Young Adult | 2009 |
Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Lymphoma, Non-Hodgkin; Protein-Tyrosine Kinases; Radioimmunotherapy; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Secondary Prevention; Signal Transduction; Sirolimus; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Reassessing the standard of care in indolent lymphoma: a clinical update to improve clinical practice.
Topics: Antibodies, Monoclonal, Murine-Derived; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Pyrazines; Radioimmunotherapy; Rituximab; Thalidomide | 2010 |
[IMiDs in hematology].
Topics: Chronic Disease; Hematologic Neoplasms; Humans; Immunologic Factors; Lenalidomide; Leukemia, Lymphoid; Lymphoma, Non-Hodgkin; Multiple Myeloma; Myelodysplastic Syndromes; Primary Myelofibrosis; Thalidomide; Waldenstrom Macroglobulinemia | 2011 |
Treatment options in Waldenstrom's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Humans; Lymphoma, Non-Hodgkin; Rituximab; Thalidomide; Waldenstrom Macroglobulinemia | 2004 |
Lenalidomide for the treatment of B-cell malignancies.
Topics: Amyloidosis; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytokines; Gene Expression Regulation, Neoplastic; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Randomized Controlled Trials as Topic; Thalidomide; Waldenstrom Macroglobulinemia | 2008 |
13 trial(s) available for thalidomide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
A phase II trial of lenalidomide plus rituximab in previously untreated follicular non-Hodgkin's lymphoma (NHL): CALGB 50803 (Alliance).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Rituximab; Survival Rate; Thalidomide | 2017 |
Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Comorbidity; Dose-Response Relationship, Drug; Drug Eruptions; Fatigue; Female; Heart Diseases; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Male; Nitrogen Mustard Compounds; Rituximab; Salvage Therapy; Thalidomide; Treatment Outcome | 2013 |
Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non-Hodgkin lymphoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Polymorphism, Genetic; Receptors, IgG; Rituximab; Thalidomide; Treatment Outcome | 2014 |
Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Rituximab; Thalidomide; Treatment Outcome | 2014 |
A phase I study of bendamustine, lenalidomide and rituximab in relapsed and refractory lymphomas.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Female; Follow-Up Studies; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Remission Induction; Rituximab; Thalidomide | 2015 |
Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Exanthema; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Prospective Studies; Rituximab; Thalidomide | 2015 |
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Italy; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Rituximab; Survival Rate; Thalidomide | 2016 |
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Hematologic Diseases; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Remission Induction; Thalidomide | 2008 |
Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Constipation; Diarrhea; Drug Administration Schedule; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Kaplan-Meier Estimate; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Recurrence; Thalidomide; Time Factors; Treatment Outcome | 2009 |
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antineoplastic Agents; Benzylamines; Boronic Acids; Bortezomib; Child; Cyclams; Europe; Female; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Myeloablative Agonists; Prognosis; Pyrazines; Thalidomide; Transplantation, Autologous; Transplantation, Homologous | 2011 |
The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Thalidomide; Treatment Outcome | 2011 |
Plerixafor for autologous peripheral blood stem cell mobilization in patients previously treated with fludarabine or lenalidomide.
Topics: Adult; Aged; Anti-HIV Agents; Antigens, CD34; Antineoplastic Agents; Benzylamines; Compassionate Use Trials; Cyclams; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Peripheral Blood Stem Cell Transplantation; Thalidomide; Time Factors; Transplantation, Autologous; Vidarabine | 2012 |
Thalidomide has limited single-agent activity in relapsed or refractory indolent non-Hodgkin lymphomas: a phase II trial of the Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Immunosuppressive Agents; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Thalidomide; Thromboembolism; Treatment Failure | 2008 |
20 other study(ies) available for thalidomide and Diffuse Mixed Small and Large Cell Lymphoma
| Article | Year |
|---|---|
Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Female; HIV Infections; Humans; Immune Checkpoint Inhibitors; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Progression-Free Survival; Retrospective Studies; Thalidomide; Time Factors | 2021 |
Sequential development of multifocal recurrent non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue and diffuse large B-Cell lymphoma in a single patient: A case report.
Topics: Adult; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Lenalidomide; Lymphadenopathy; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Parotid Gland; Positron Emission Tomography Computed Tomography; Rituximab; Thalidomide; Transplantation, Autologous; Treatment Outcome | 2018 |
Non-Hodgkin's lymphomas, version 1.2013.
Topics: Antineoplastic Agents; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Thalidomide; Virus Activation | 2013 |
Designs for randomized phase II clinical trials with two treatment arms.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Bias; Clinical Trials, Phase II as Topic; Endpoint Determination; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Randomized Controlled Trials as Topic; Recurrence; Research Design; Rituximab; Thalidomide; Treatment Outcome | 2013 |
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation.
Topics: Adult; Aged; Angiogenesis Inhibitors; Combined Modality Therapy; Disease Progression; Drug Evaluation; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retrospective Studies; Thalidomide; Treatment Outcome; Young Adult | 2013 |
Lenalidomide monotherapy in heavily pretreated patients with non-Hodgkin lymphoma: an Italian observational multicenter retrospective study in daily clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Disease-Free Survival; Female; Humans; Immunologic Factors; Italy; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Off-Label Use; Retrospective Studies; Survival Rate; Thalidomide | 2015 |
Towards a chemotherapy-free approach in indolent lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Female; Humans; Lenalidomide; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Neoplasm Recurrence, Local; Rituximab; Thalidomide | 2014 |
Mobilization and transplantation patterns of autologous hematopoietic stem cells in multiple myeloma and non-Hodgkin lymphoma.
Topics: Benzylamines; Cyclams; Cyclophosphamide; Data Collection; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Immunologic Factors; Immunosuppressive Agents; Lenalidomide; Lymphoma, Non-Hodgkin; Multiple Myeloma; Practice Patterns, Physicians'; Thalidomide | 2015 |
Lenalidomide monotherapy as salvage treatment for recurrent primary CNS lymphoma.
Topics: Aged; Angiogenesis Inhibitors; Central Nervous System Neoplasms; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Salvage Therapy; Thalidomide | 2015 |
Lenalidomide in non-Hodgkin lymphoma: biological perspectives and therapeutic opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Lenalidomide; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Neoplasm Recurrence, Local; Thalidomide; Treatment Outcome | 2015 |
The efficacy of lenalidomide combination therapy in heavily pretreated non-Hodgkin lymphoma patients: an Italian observational, multicenter, retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Italy; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Middle Aged; Remission Induction; Retrospective Studies; Survival Analysis; Thalidomide; Treatment Outcome | 2017 |
Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.
Topics: Adenine Nucleotides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bendamustine Hydrochloride; Clofarabine; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Nitrogen Mustard Compounds; Phosphoinositide-3 Kinase Inhibitors; Rituximab; Thalidomide | 2010 |
Myocarditis during lenalidomide therapy.
Topics: Aged, 80 and over; Antineoplastic Agents; Autopsy; Dexamethasone; Female; Humans; Lenalidomide; Lymphoma, Non-Hodgkin; Multiple Organ Failure; Myocarditis; T-Lymphocytes; Thalidomide | 2010 |
Innovative strategies in lymphoma therapy.
Topics: Alemtuzumab; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cancer Vaccines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Forecasting; Genetic Therapy; Humans; Immunoconjugates; Immunotherapy; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Prednisone; Protease Inhibitors; Proteomics; Pyrazines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Rituximab; Signal Transduction; Survival Analysis; Thalidomide; Time Factors; Vincristine | 2003 |
45th Annual Meeting of the American Society of Hematology December 6-9, 2003.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Clinical Trials as Topic; Hematology; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Multicenter Studies as Topic; Multiple Myeloma; Oxides; Prognosis; Protein-Tyrosine Kinases; Recurrence; Risk; Rituximab; Salvage Therapy; Thalidomide; Time Factors; ZAP-70 Protein-Tyrosine Kinase | 2004 |
Long-term outcome of intractable ulcerating enterocolitis of infancy.
Topics: Adolescent; Adult; Azathioprine; Child; Child, Preschool; Chronic Disease; Colectomy; Colitis, Ulcerative; Cyclosporine; Enterocolitis; Epstein-Barr Virus Infections; Female; Follow-Up Studies; Humans; Immunoglobulins; Immunosuppressive Agents; Infant; Infant, Newborn; Lymphoma, Non-Hodgkin; Lymphoproliferative Disorders; Male; Steroids; Thalidomide; Time Factors; Treatment Outcome | 2005 |
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Apoptosis; Cell Line, Tumor; Cell Proliferation; DNA; Drug Therapy, Combination; Female; Flow Cytometry; Humans; Immunologic Factors; Killer Cells, Natural; Lenalidomide; Lymphoma, Non-Hodgkin; Male; Mice; Mice, SCID; Rituximab; Survival Analysis; Thalidomide; Treatment Outcome; Xenograft Model Antitumor Assays | 2005 |
Acute renal failure caused by renal infiltration by hematolymphoid malignancy.
Topics: Acute Kidney Injury; Allopurinol; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Kidney; Leukemia, Plasma Cell; Leukemic Infiltration; Lymphoma, Non-Hodgkin; Middle Aged; Radiography; Thalidomide; Treatment Outcome | 2006 |
Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Coculture Techniques; Drug Screening Assays, Antitumor; Flow Cytometry; Humans; Killer Cells, Natural; Lenalidomide; Leukocytes, Mononuclear; Lymphoma, Non-Hodgkin; Male; Neoplasms; Prostatic Neoplasms; Thalidomide | 2008 |
37th Annual American Society of Clinical Oncology Meeting. San Francisco, CA. May 12-15, 2001.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Adhesion Molecules; Cyclophosphamide; Dacarbazine; Doxorubicin; Etoposide; Hodgkin Disease; Humans; Immunosuppressive Agents; Immunotoxins; Lectins; Leukemia, Hairy Cell; Lymphoma, Non-Hodgkin; Multiple Myeloma; Rituximab; Sialic Acid Binding Ig-like Lectin 2; Thalidomide; Vinblastine | 2001 |